Growth-Hormone Secretagogues as a Research Class
Growth-hormone secretagogue is a research-class label, not a single chemical family. It groups compounds by the target that preclinical studies have examined rather than by a shared backbone, which is why two materials in the same class can look very different on a certificate of analysis. This note describes what the label means, the two subtypes represented in the Advanced Sequence catalogue, and the documented identity fields that keep them apart.
What the class label describes
A secretagogue, read literally, is a substance that has been studied in the context of triggering a secretion. In the growth-hormone research literature the term is applied to compounds investigated for their interaction with two distinct receptor systems: the growth-hormone secretagogue receptor, historically associated with ghrelin-mimetic peptides, and the growth-hormone-releasing hormone receptor, associated with releasing-factor analogs. The important point for a laboratory is that the class name reports a research context, not an outcome. Grouping a material here says that literature has examined it against one of those targets, and nothing more. It does not assert that the compound raises, releases, or affects anything in any subject.
Because the grouping is functional rather than structural, the class spans more than one chemical design. Reading these materials well means treating the class as a filing category and then returning to the individual identity record for the chemistry that actually distinguishes one vial from another.
Two subtypes, two identity records
The catalogue represents the class with two peptides that sit in different subtypes. Only the fields documented for each are shown below; where a value such as a molecular formula or mass is not part of the supplied record, it is deliberately omitted rather than estimated.
| Field | Ipamorelin | CJC-1295 |
|---|---|---|
| Class descriptor | Pentapeptide secretagogue | Modified GRF analog |
| Sequence descriptor | 5 amino acids | 29-44 variants |
| CAS number | 170851-70-4 | 863288-34-0 |
| Reported purity | 99.3% | 99.1% |
| Catalogue sizes | 5 mg, 10 mg | 2 mg, 5 mg |
Ipamorelin is documented as a pentapeptide, a five-residue secretagogue in the ghrelin-mimetic subtype. Its record stops at a class and a residue count, so a responsible write-up stops there too and does not attach a full residue string pulled from memory. CJC-1295 is documented as a modified growth-hormone-releasing-factor analog referencing the 29-44 region, a different design that belongs to the releasing-factor subtype. The two share a research class and almost nothing else on paper, which is exactly why the class label alone is never enough to confirm what is in a vial.
Why the CAS number carries the weight
Since the subtypes differ in structure, the CAS registry number is the field that most reliably separates them. A shared class name can appear on unrelated preparations, but the registry number is a stable, unique handle for a defined substance. Confirming 170851-70-4 for one material and 863288-34-0 for the other is a firmer check than matching the words secretagogue or analog, which can travel loosely across catalogues.
The two subtypes are also documented at different levels of structural detail, and a careful record respects that. Ipamorelin’s supplied data stops at a pentapeptide class and a five-residue count, so a defensible write-up cites exactly those fields and no invented residue string or mass. CJC-1295’s record references the 29-44 region of a modified releasing factor and a set of documented variants, which is a different kind of descriptor entirely. Reading the two side by side is a useful reminder that within a single research class the available identity information is not uniform, and that the correct response to a missing field is to leave it out rather than to fill it from a similar-looking compound elsewhere in the catalogue.
How the class is studied, described neutrally
Research interest in this class has centred on receptor-level interactions examined in vitro and in defined preclinical models. The honest register for describing that work is attributive and past-referential: a compound has been investigated in the context of a receptor system, or research has characterised its binding behaviour under stated assay conditions. That phrasing reports what was measured without asserting an effect. For the methodology behind those measurements, the note on how receptor-binding assays are used in peptide research covers the formats and their limits, and the wider compound classes archive places this group alongside the others.
What the class framing must never become is a benefit claim. The presence of a target in the literature is not evidence of an outcome, and a laboratory documenting these materials should keep the distinction visible in its own records and labelling.
Handling and catalogue notes
Both materials are supplied as research-use-only reference compounds. As lyophilized peptides they are handled cold and dry and protected from light and moisture; general storage practice for freeze-dried solids is covered separately and does not include preparation amounts, concentrations, schedules, or routes, which fall outside a class overview. Product-level identity records for Ipamorelin and CJC-1295 list the documented fields for each, and the full catalogue is reachable from the shop.
Read this way, the class is a useful first filter and a poor final answer. It tells a researcher which shelf a material belongs on and which literature to consult, but the vial-level decision, the one that determines what actually goes into an experiment, always returns to the registry number, the sequence descriptor, the reported purity, and the certificate that should accompany the lot. A class label that is treated as a shortcut past those fields is precisely where documentation errors begin.
Common questions
What makes a compound a growth-hormone secretagogue?
It is a research-class label for compounds studied against the growth-hormone secretagogue receptor or the growth-hormone-releasing hormone receptor. The grouping reports a research context, not an outcome, and covers more than one chemical design.
Are Ipamorelin and CJC-1295 the same kind of peptide?
No. Ipamorelin is documented as a five-residue pentapeptide secretagogue; CJC-1295 is a modified growth-hormone-releasing-factor analog referencing the 29-44 region. They share a research class but differ in structure, so their CAS numbers are the reliable way to tell them apart.
Does the class label imply the compounds work?
No. The label only indicates the receptor context that literature has examined. It is not evidence of any effect, and these materials are supplied strictly for laboratory research use.